MiniMed Group stock
MMEDNASDAQMiniMed Group, Inc., HealthcareISIN US60365F1093
47Score 47 out of 100, Weak
Price and trend
65 / 100
Price history
−3.3% since 2026The chart shows daily closing prices since 6 Mar 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 25% below its 52-week high. Largest decline since 6 Mar 2026: 42% (March 2026 to May 2026).
Chart figures for advanced users
- SMA 50$19.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.88
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$10.80
- The lowest closing price of the last twelve months.
- Resistance$23.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- In fiscal 2025 it reported revenue of $3.1B (up 14.3% year on year) and a loss of $331M.
- For fiscal 2026, analysts expect on average revenue of $3.44B (up 10.9%) and adjusted earnings per share of $0.70.
- MEQIRI Score 47 out of 100 (Weak): rank 430 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $207M, financial debt $59M.Stability 77
- Share buybacksShare count down 9% since 2022.
Weaknesses
- Loss-makingLoss of $329M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$316M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 58% a year over the last 12 months.
Its standout strengths are momentum and stability, while valuation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
OvervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 31 Jul 2026, revenue rose 16.6% on the same quarter a year earlier. Revenue has grown solidly since 2022, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 54%, operating 2%, net −11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 30 Dec 2026in 48 days
- Last reported
- 1 Sep 2026EPS reported $0.12 (expected $0.12)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.70+0.5%
- Revenue
- $3.44B0.0%
- Earnings per share
- $0.71+0.1%
- Revenue
- $3.72B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +17.3%Fiscal 2027 organic revenue growth outlook raised to about 10.5% from about 10%, with the adjusted EBITDA margin guidance of about 16% reaffirmed.
“Given our strong start to the year and execution across the business, we're raising our fiscal 2027 organic revenue growth outlook to approximately 10.5% from our prior guidance of approximately 10%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 1 Sep 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at MiniMed Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in the Healthcare sector
The next larger and next smaller companies by market value
ETFs that hold MiniMed Group
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.17% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.17% | 0.30% | €4.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 24 Apr 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.